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Degenerative joint disease is one of the main causes of equine early retirement from pleasure riding or a
performance career. The disease is initially triggered by an abnormal loading of normal cartilage or a normal
loading of abnormal cartilage. This primary insult is accompanied with joint inflammation, which leads to
further progressive degeneration of the articular cartilage and changes in the surrounding tissues. Therefore, in
search for an effective treatment, 75 adult horses with early signs of degenerative fetlock joint disease were
enrolled in a randomized, multicenter, double-blinded, and placebo-controlled study. Fifty animals were in-
jected intra-articularly with the investigational veterinary product (IVP) consisting of allogeneic chondrogenic
induced mesenchymal stem cells (ciMSCs) with equine allogeneic plasma, and 25 horses were injected with
0.9% NaCl (saline) control product. From week 3 to 18 after treatment, lameness scores (P< 0.001), flexion test
responses (P < 0.034), and joint effusion scores (P< 0.001) were remarkably superior in IVP-treated horses.
Besides nasal discharge in both treatment groups, no adverse events were observed during the entire study
period. On long-term follow-up (1 year), significantly more investigational product-treated horses were working
at training level or were returned to their previous level of work (P< 0.001).
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Introduction
Just like in human medicine, degenerative joint diseaseis a well-known and common problem in equine medicine.
The disease starts with an injury or pathology in the soft
tissues, subchondral bone, or articular cartilage of the joint or
with a combination of the above. This initial trigger leads to
progressive degradation of the articular cartilage together with
changes in the bone and the surrounding soft tissues [1].
Whatever the primary cause may be, joint inflammation or,
more specifically, synovitis is an important aggravator or
mediator of degenerative joint disease. Indeed, synovitis leads
to the production of proinflammatory cytokines and matrix-
degrading enzymes, contributing to the disease development
[2,3]. Moreover, synovitis causes pain and joint effusion,
which contributes to joint (micro-)instability.
Approximately 25% of horses are affected with some stage
of degenerative joint disease at some point of their lifetime,
be it an early stage mainly characterized by an inflammatory
component and altered cartilage metabolism or a more
chronic stage characterized by bony changes with intermittent
inflammatory flares and severe cartilage destruction [4,5].
Considering that there are *5.7 million horses registered in
official databases in Europe [6] and 9.2 million in the United
States [7], and that, according to an official European market
study from Euromonitor, *25% of injured horses visit a
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veterinarian regularly, 356,000 European horses and 575,000
American horses that visit a veterinarian suffer from osteo-
arthritis at a certain point in their life.
Currently, in both human and veterinary medicine, differ-
ent treatments are available to ease the pain and increase the
patient’s comfort. Similar to human medicine, the most fre-
quently used medicinal products in equine practice for early-
stage joint inflammation are nonsteroidal anti-inflammatory
drugs (NSAIDs), corticosteroids, glucosamine, chondroitin
sulfate, and hyaluronic acid [8–10].
NSAIDs moderately reduce the pain and inflammation
associated with degenerative joint disease. However, they
require daily administration and gastrointestinal and kidney
problems arewell-known side effects [10,11]. Corticosteroids
effectively reduce inflammation and pain, but often have to be
administered on repeated occasions to sustain their effect.
Moreover, corticosteroids are sometimes disputed, since they
potentially have a detrimental effect on the already compro-
mised cartilage metabolism [5,11]. In addition, they are most
effective when there is a strong inflammatory component and
less when the main problem is tissue degradation.
Hyaluronic acid has been reported to reduce inflamma-
tion, especially when administered intravenously. However,
when administered intra-articularly, this effect is far less
pronounced and it has been reported to cause flare reactions
[11]. Because of these flare reactions, hyaluronic acid is
often combined in practice with corticosteroid for intra-
articular administration. A recent study on intra-articular use
of hyaluronic acid has, however, reported no benefit of using
hyaluronic acid combined with triamcinolone over triam-
cinolone alone [12].
Glucosamine and chondroitin sulfate are available as
nutraceuticals and are popular in equine practice [13].
However, since nutraceuticals are not regulated, they are not
standardly tested on safety and efficacy, and often infor-
mation on their oral bioavailability is lacking [8,11].
Thus, currently, most treatments focus on reducing the
symptoms of degenerative joint disease, but not to prevent
further degradation. More recently, in search for treatment
alternatives, cell-based therapies are being investigated be-
cause of their biological nature and regenerative potential
[14–17]. Indeed, there are indications that intra-articular
application of mesenchymal stem cells (MSCs) improves
cartilage healing [14–16]. In addition, in vitro observa-
tions have demonstrated that chondrogenic induced MSCs
produce cartilage-specific substances, such as aggrecan,
glycosaminoglycans, and collagen type II, which could aid
cartilage repair [17–20].
Despite the mode of action of MSCs being largely un-
defined, several mechanisms observed in in vitro and animal
experiments are assumed to be responsible for the effect
seen in patients [21]. The classic hypothesis that MSCs
migrate to the site of injury, integrate in the tissue, and
differentiate into functional cells is being progressively
abandoned. Currently, it is inferred that MSCs heal injured
tissue by using paracrine signals, cell-cell contact through
nanotubes, cell fusion events, or by the secretion of extra-
cellular vesicles [21,22]. These mechanisms are deemed
responsible for the anti-inflammatory and angiogenic effect
MSCs display under certain circumstances and the reason
they can stimulate local cell survival and proliferation
[21,22].
MSC-based therapies would thus potentially provide a
more durable solution to degenerative joint disease, since they
can possibly stimulate local cartilage repair and thus retard or
even reverse the disease process. However, because experi-
mental models do not completely resemble clinical pathology
of naturally occurring degenerative joint disease, veterinary
patient studies using autologous or allogeneic MSCs have
also been conducted. These studies report the safety and ef-
ficacy of stem cell treatments based on an average amount of
horses that were able to return to work or to return to previous
levels of performance, which varied from 76% to 86% de-
pending on the affected joints [23,24]. Nevertheless, these
studies were not blinded and did not include control groups.
Thus, although horse owners hesitate to participate in
clinical trials with placebo treatments, it is imperative to per-
form double-blinded superiority (compared to a placebo) or
noninferiority (compared to a registered medicinal treatment)
clinical trials to evaluate a new therapy for its effectiveness.
Veterinary MSC treatments are defined as a veterinary me-
dicinal product according to the pharmaceutical act of the EU
[Art. 1 No. 2 Directive 2001/82/Ethics committee (EC)] [25]
and are thus subjected to strict regulations. In humanmedicine,
1,052 novel clinical stem cell trials have been identified so far,
but only 3.5% resulted in a successful marketing authorization
[26], indicating the difficulty to demonstrate evidence-based
efficacy and/or safety of a cell-based therapy.
To the authors’ knowledge, in veterinary medicine, no
clinical field trial for cell-based products in equine ortho-
pedics has been reported to date. However, to prove safety
and efficacy of a novel stem cell-based product in horses, a
field trial should be conducted compliant to Good Clinical
Practice (GCP), as described by the Veterinary International
Conference on Harmonization (VICH) Guideline number 9
[Committee for Medicinal Products for Veterinary Use
(CVMP)/VICH/595/98]. Agreed by EU, Japan, and the
United States, this quality standard provides detailed guid-
ance on the requirements of clinical studies needed to obtain
marketing authorization of new veterinary medicinal prod-
ucts in these markets.
Thus, based on this guideline, a field trial should be
controlled, double blinded, multicenter, and randomized to
effectively evaluate efficacy and safety of a cell-based
therapy for treatment of naturally occurring degenerative
joint disease in horses.
Therefore, to accommodate current legislation and to
address the scientific need for a more durable solution, a
placebo-controlled, double-blinded, multicenter, random-
ized GCP-compliant clinical field trial was performed, eval-
uating the safety and efficacy of equine MSCs as a treatment
for naturally occurring degenerative joint disease (or chronic
joint inflammation as an early stage of degenerative joint
disease) in horses.
Since it has been reported that the microenvironment in
inflamed joints has an influence on the paracrine signaling of
equine MSCs [27], the MSCs used in this study were chon-
drogenically primed to stimulate the cells to produce the
correct paracrine substances. Moreover, equine allogeneic
plasma (EAP) was added to the MSCs before injection, be-
cause this has been shown to increase clinical improvement
of horses with degenerative joint disease of the fetlock [17].
The hypothesis of this study was that allogeneic chon-
drogenic induced MSCs (ciMSCs) combined with EAP
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would be a safe and effective treatment, and would have
superior and clinically relevant outcome compared to a
placebo (saline) for the treatment of mild-to-moderate
(early) degenerative fetlock joint disease in 75 horses.
Materials and Methods
Regulatory requirements and animal
welfare regulations
This study was carried out in accordance with recom-
mendations of the Animal Welfare Department of the Belgian
Federal Public Service of Health. The study protocol was
approved (EC_2015_003) by the Ethics Committee of Global
Stem cell Technology (Permit Number: LA1700607). In ad-
dition, the study was conducted according to European and
national regulatory requirements and in compliance with
Directive 2001/82/EC, VICH GL9 (GCP, June 2000), EMA/
CVMP/Efficacy Working Party (EWP)/81976/2010 (Guide-
line on statistical principles for clinical trials for veterinary
medicinal products).
The medicinal products in this trials were produced ac-
cording to Good Manufacturing Practice (GMP) (certifi-
cates: BE/GMP/2015/082 and BE/GMP/2016/069) and with
manufacturing authorization 1868V for veterinary medicinal
products. The field study was approved and received clinical
trial authorization permit 0002829 from the Belgian federal
agency for medicines and health products. Before enrol-
ment, written owner consent was obtained from each owner
of horses participating in the study.
Investigational veterinary product
and control product
The investigational veterinary product (IVP) consisted out
of a proprietary combination of allogeneic ciMSCs and EAP.
Preparation of the IVP is briefly described below. Saline
(0.9% NaCl=Vetivex 9mg/mL; Dechra Limited, Stafford-
shire, United Kingdom) was used as the control product (CP).
Isolation and chondrogenic induction of MSCs. In total, 50mL
of blood was collected in sterile ethylenediaminetetraacetic
acid (EDTA) tubes from the vena jugularis of a 6-year-old
donor gelding, which was tested for 32 different transmit-
table diseases at Bo¨se laboratory (Harsum, Germany), in
agreement with the European Medicines Agency (EMA)
requirements. This donor horse was further not involved in
the study in any way. Approval of the ethics committee was
obtained for blood sampling of the donor horse (EC_2012_001
and EC_2016_003).
Isolation, characterization, and freezing of the interme-
diate cell stock were performed at P5 as described previ-
ously [20]. Cells were thawed, cultured, and subsequently
chondrogenically induced from P9 to P10 using a proprie-
tary method and media. The cells were characterized by
assessing the total cell number, viability, and sterility, gene
expression of a chondrogenic marker (cartilage oligomeric
protein: COMP), and the presence of cell surface markers
[cluster of differentiation (CD45), major histocompatibility
complex (MHC) II, CD29, CD44, and CD90].
Chondrogenic induced MSCs were trypsinized, re-
suspended in 1mL of Dulbecco’s modified Eagle’s medium
low glucose (DMEM LG) with 10% of dimethyl sulfoxide
(Sigma) at a concentration of 2· 106 cells per mL, and
frozen before being shipped on dry ice for clinical appli-
cation. Viability and gene expression of COMP were again
assessed after 6 and 12 months of frozen storage to assess
ciMSC batch stability.
Preparation of EAP. In total, 900mL of peripheral blood
was collected from a single donor horse (a gelding of 14
years) in a citrate phosphate dextrose adenine-1 single blood
bag (Terumo) for EAP preparation. This donor horse was a
different individual from the stem cell donor, but was also
tested for 32 different transmittable diseases at Bo¨se labo-
ratory, in agreement with the EMA requirements. This do-
nor horse was also further not involved in the study in any
way.
One hundred samples of 1mL EAP were prepared as
previously described by our group [28,29]. Each sample
contained *85 · 106 platelets and was frozen and stored at
-80C until clinical application.
Patient inclusion and exclusion criteria
In total, 75 warmblood horses, 3 to 23 years of age, with
recurrent lameness were enrolled in this study: 22 mares, 16
geldings, and 37 stallions. The MHC status of each indi-
vidual patient was not determined. However, horses were
not expected to be MHC matched with our MSC donor.
Thus, most likely, horses were semiallogeneic or full allo-
geneic for MHC molecules.
To be included, horses had to present grade 2 or 3
lameness on the American Association of Equine Practi-
tioners (AAEP) scale associated with (early staged) fetlock
degenerative joint disease lasting for at least 2 months (early
staged degenerative joint disease was defined as joint in-
flammation lasting over 2 months). In addition, lameness
had to be confirmed by a positive intra-articular anesthesia
of the fetlock and a positive flexion test. The fetlock joint
also needed to show at least one sign of inflammation
(swelling, pain on palpation, or heat assessed by palpation).
Horses were excluded if they received an unauthorized
pretreatment (eg, corticosteroids), which still could have an
effect on the pathology, if they had a severe medical con-
dition that, in the opinion of the investigator, would have
compromised their safe participation in the study, and if the
horses had any condition, actual or anticipated, which the
investigator felt would restrict or limit their successful
participation for the entire duration of the study.
Other exclusion criteria consisted of previous participation
in a stem cell study with the treated joint, lameness on more
than one limb, AAEP scores of 1, 4, or 5, or lameness due to
any other locomotion problem (nervous system and back
problem). Moreover, a narrowed joint interspace reducing ‡1/
3 of the normal fetlock joint space on lateromedial (LM) or
dorsoplantar (DP) X-ray was not allowed. All horses were
withdrawn from medication from study start to study com-
pletion. In addition, no therapies were offered at the study end.
Blinding and randomization
Due to the color difference between the IVP and the CP,
the study was blinded by using separate personnel for clinical
examinations (investigator and examining veterinarian) and
administration of treatments (dispenser); so there were two
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separate teams (examining vet and dispenser) at both study
sites (two veterinary clinics) performing the different tasks
within the study. Owners were not present when the treat-
ment was administrated, so they were also blinded to which
treatment their horse had received. A random treatment al-
location plan was prepared for each study site and provided
separately to the dispenser. The investigator/examining vet-
erinarian assigned a unique ID number to the animal. The
random treatment allocation plan was created using a block
size of 3, whereby a ratio of 2:1 horses (IVP:CP) was allo-
cated to the treatment groups.
Treatment and rehabilitation protocol
On day 0, all inclusion and exclusion criteria were eval-
uated, an intra-articular anesthesia was performed on the
affected joint, and LM and DP X-rays were taken. The
horses were treated *24 h later (day 1) to avoid mixing
between anesthetics and equine MSCs in the joint, which
could cause severe cell damage [30]. On day 1, each horse
was sedated using detomidine hydrochloride (Detonervin
10mg/mL, 0.5mL IV; Le Vet B.V., The Netherlands), and
ketoprofen (Ketofen 10%; Merial Animal Health, Belgium,
10mL IV) was given as concomitant nonsteroidal anti-
inflammatory treatment before intra-articular application of
2mL of the IVP or 2mL of the CP. For the IVP adminis-
tration, both the EAP (1mL) and ciMSCs (1mL) were
thawed at 25C–37C and drawn into one syringe. The IVP
was injected immediately after mixing.
The first 3 days of the study, the horses were walked up
and down a corridor only. After that, they were walked with
the rider up to 1 week, followed by walking and trotting
with the rider up to the first clinical evaluation at week 3.
Depending on the clinical status of the horse, they gradually
returned to work by including canter exercises on week 4
and return to full work at week 6 or continued restricted
walking and trotting exercises up to week 6. The rehabili-
tation occurred in the owners care or at the veterinary clinic
the first 3 days of the study. The remainder of the study, the
rehabilitation occurred in the owners care.
Table 1. Overview of the Score Systems Used by the Examining Veterinarians for Assessing
Lameness, Response to Flexion Test, Joint Effusion, Heat at Palpation, and Pain to Pressure,
and the Scores Attributed by the Owners During the Owner Questionnaires
Parameter Score Clinical implication
Veterinary scoring
AAEP grading 0 No lameness
1 Lameness not consistent, regardless of circumstances
2 Lameness consistent under certain circumstances
3 Lameness consistently observable on a straight line
4 Obvious lameness: marked nodding or shortened stride
5 Minimal weight-bearing lameness in motion or at rest
Flexion test 0 No flexion response
1 Mild flexion response
2 Moderate flexion response
3 Severe flexion response
Joint effusion 0 No swelling
1 Mild swelling
2 Moderate swelling
3 Severe swelling
4 Extreme swelling (also periarticular)
Heat at palpation 0 No increased temperature sensation
1 Mild increased temperature sensation
2 Moderate increased temperature sensation
3 Severe increased temperature sensation
Pain to pressure 0 No pain to pressure
1 Mild pain to pressure
2 Moderate pain to pressure
3 Severe pain to pressure
Owner scoring
Horse improvement 0% Not at all
20% Marginal improvement
40% Mild improvement
60% Moderate improvement
80% Remarkable improvement
100% No more discomfort noticeable
Current working status 00 Failure to return to work
0 Rehabilitating
1 Return to work
2 Return to previous level of work
AAEP, American Association of Equine Practitioners.
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Evaluation protocol
On day 0 and at week 3 and 6, a visual lameness as-
sessment and flexion test were performed on all horses in-
cluded in the study, using the AAEP score system and the
score system depicted in Table 1, respectively. On day 1 and
2, a reduced lameness examination was performed by
walking the horse up and down a corridor and evaluating
lameness based on the following scores:
 no lameness visible (score 0),
 lameness difficult to observe and not consistent (score 1)
 lameness obvious at walk (score 2)
 minimal weight bearing (score 3).
Based on other clinical studies [17,23], week 6 was de-
fined as the time point to evaluate the primary efficacy
endpoint to observe a sustained clinical effect of treatment.
A relevant clinical improvement, the primary efficacy cri-
terion, was considered a reduction of AAEP lameness score
from 2 or 3 (clear clinical lameness) at inclusion to an
AAEP score of 0 or 1 (no or inconsistent clinical lameness).
The total duration of the study per animal was allowed to
range from 37 to 47 days (day 0 to week 6– 5 days). At
week 6, the owners were also consulted to rate the condition
and improvement of their horse (Table 1). Further veterinary
evaluation (joint and lameness assessment scored according
to Table 1) was planned for week 12 – 1 week and week
18 – 1 week. In case the patient could not be presented to the
investigator, an owner questionnaire was used to obtain data
from the patient. In addition, at week 18 and 1 year after
treatment, owners were contacted again to inform about the
work status of their horse.
Any observation in animals that was unfavorable and un-
intended, and occurred after the use of the IVP or CP was
defined an adverse event (AE). A suspected adverse drug
reaction was defined as an AE where a relation to treatment
was suspected. A serious adverse event (SAE) was defined as
any AE that resulted in death, was life-threatening, or resulted
in persistent or significant disability/incapacity. As lameness
and joint abnormalities in the treated affected limb were re-
corded separately as they were part of the efficacy evaluation
criteria, these were not documented separately as AEs.
A clinical examination was performed of each horse on
day 0, 1, and 2 and at week 3 and 6, and whenever requested
by the owner, and consisted of temperature, respiratory rate,
and heart rate measurements combined with a general body
examination. Local clinical inflammatory parameters, such
as heat at palpation, pain to pressure, and joint swelling
were also scored at these time points (Table 1).
Statistical analysis
The sample size of the study was calculated using SAS
statistical analysis software (Version 9.3) of the SAS In-
stitute, Inc. (Cary, NC), so a two-group w2 test with a 0.05
two-sided significance would have 80% power to detect the
difference between a control proportion, p1, of 0.3 (30%
estimated success) and an IVP proportion, p2, of 0.6 or 0.7
(60%–70% estimated success). Based on this calculation
with an unbalanced distribution of group (IVP:CP = 2:1), at
least 50 animals in the IVP treatment group and 25 animals
in the CP per-treatment group were shown to be sufficient to
demonstrate potential statistical superiority.
All data were collected on pre-established data capture
forms. Then data were entered to a specifically established
electronic database, verified, and inconsistencies sorted.
Statistical analysis was performed on the data transferred
from that database to SAS statistical analysis software
(Version 9.3) of the SAS Institute, Inc. The difference in
relevant clinical improvement scores was compared be-
tween groups at different time points using Fisher’s exact
test. To compare all clinical and owner scores presenting
number and percent of each score category, the Mantel–
Haenszel test was used. The difference in working status
was compared using Mann–Whitney U test. The percentage
of animals with AEs was compared between groups using
Fisher’s exact test. A 5% level of significance was used to
assess statistical differences.
Results
Isolation and characterization of MSCs
The intermediate cell stock displayed all properties to be
characterized as MSCs. Briefly, they attached to plastic,
trilineage differentiation was performed successfully, and
MSCs were positive for CD29 (100%), CD44 (100%), and
CD90 (100%) and negative for CD45 (1%) and MHC II
(0%) (Fig. 1). The average population doubling time over 10
passages was 1.4 and passage 10 ciMSCs displayed 96%
viability, an MSC immunophenotype (100% CD29, 87%
CD44, 98% CD90, 2% CD45, and 0% MHC II), and a 4.4-
fold COMP increase as a marker for chondrogenic induction
[17]. After 6 months of frozen storage, 82% viability and
4.6-fold COMP change were present. At 12 months, via-
bility remained above 80% and a 4.2-fold COMP change
was present. All horses were treated within this period after
MSC production.
Clinical outcome
All 75 horses included in this study showed initially a
moderate lameness (score 2–3 out of 5 on the AAEP scale;
Fig. 2), mild-to-moderate response to flexion test (score 1–2
out of 3; Fig. 3), and mild-to-moderate joint swelling (score
1–2 out of 4; Fig. 4). The clinical signs in both treatment
groups upon inclusion were comparable and did not show
any significant difference between groups (Table 2).
At week 3 after treatment, the AAEP lameness score was
significantly (P< 0.001) improved in the IVP group compared
to the CP group with relevant clinical improvement (decrease
to AAEP score 0 or 1) in 70% of the animals (Fig. 2). At
week 6, relevant clinical improvement as a primary efficacy
criterion was observed in 78% of the IVP-treated horses in
comparison to 24% in the CP-treated horses (Fig. 2). This
difference of 54.0% was significant, and superiority was
shown for IVP compared to CP (P< 0.001). The evaluation of
the AAEP lameness scores at week 12 (92% vs. 36%) and 18
(84% vs. 17%) statistically (P< 0.001) confirmed a long-term
clinical improvement in the IVP group when compared to the
CP group (Fig. 2). In the CP-treated group, 64% of the ani-
mals still showed a lameness score of 2 or 3 at week 12 and
83% at week 18 (Fig. 2). The onset of a clinically relevant
improvement with the IVP treatment was shown as early as
week 3, and this effect continued until week 18.
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FIG. 2. The distribution of
horses (in percentages) over the
AAEP score categories per
time point for the IVP-treated
group and placebo control
(CP)-treated group. The aster-
isk (*) indicates a significant
difference in frequency of
scores between the two treat-
ments groups (P<0.001).
AAEP, American Association
of Equine Practitioners; CP,
control product; IVP, investi-
gational veterinary product.
FIG. 1. Representative flow cytometric images of positive (CD29, CD44, andCD90) and negative (CD45 andMHC II)MSC
markers. Adipogenic differentiation was confirmed with Oil Red O staining, osteogenic differentiation with alizarin red S and
alkaline phosphatase staining, and chondrogenic differentiation with alcian blue staining. Differentiated cells demonstrated
morphological changes and positive staining areas, whereas undifferentiated cells remained spindle shapedwithout convincing
staining. CD, cluster of differentiation; MHC, major histocompatibility complex; MSC, mesenchymal stem cell.
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The distribution of scores of the secondary efficacy criterion
flexion test response and joint swelling was significantly dif-
ferent between groups at all postbaseline examinations, week
3, 6, 12, and 18, with lower scores in the IVP-treated animals
than in CP-treated animals (Figs. 3 and 4). At week 3, no
flexion response was observed in 38% of IVP-treated horses,
which was significantly higher than the 20% of CP-treated
horses (P< 0.05) (Fig. 3). In the CP group, the percentage of
animalswith a negative response toflexion decreased over time
toward 8% of the horses at week 12 and 18 (Fig. 3). In the IVP-
treated group, the percentage of negative flexion response was
84%atweek6 and reduced to 75%atweek12 and 62%atweek
18, which was significantly better than in the animals of the CP
group at all time points (P< 0.001) (Fig. 3).
Atweek6, owners rated at least an80%improvement in72%
of the IVP-treated animals. This was significantly more
(P< 0.001) than for the CP-treated horses (Table 3 and Fig. 5).
At week 12 and 18, one horse of the IVP and CP group, re-
spectively, was not presented for follow-up examination. The
owner questionnaire indicated that one of these animals
FIG. 3. The evolution of the
percentage of horses per flex-
ion test score category over
time for the IVP-treated group
and placebo control (CP)-
treated group. The asterisk (*)
indicates a significant differ-
ence in frequency of scores
between the two treatments
groups (P< 0.05 for week 3
and P< 0.001 for weeks 6, 12,
and 18, respectively).
FIG. 4. The distribution of
horses (in percentages) over the
joint effusion score categories
per time point for the IVP-
treated group and placebo
control (CP)-treatedgroup.The
asterisk (*) indicates a signifi-
cant difference in frequency of
scores between the two treat-
ments groups (P< 0.001).
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returned to work (IVP treatment) and the other animal was still
rehabilitating (CP group).
There was a significant difference in working status of
animals between the IVP and CP group (P < 0.001) at every
time point after baseline (Fig. 6). At week 6, 30% of the
horses in the IVP group already returned to their previous
level of work compared to none of the horses in the CP
group. In addition, 42% of the horses in the IVP group were
working at training level compared to none of the CP group
horses. At week 18, the percentage of horses that returned to
their previous level of work increased to 42% in the IVP
group, while in the CP group, this was still 0% (Fig. 6).
Therefore, at week 18, in the IVP group, 82% of the horses
returned to some level of work (working at training lev-
el+returned to previous level) compared to 16% in the CP
group. One year after treatment, in the IVP group, 37% of
the horses were working at training level compared to 8% of
the horses treated with CP. Moreover, 47% of the horses
treated with IVP returned to their previous level of work,
compared to none of the horses treated with CP (Fig. 6).
Concomitant medication after study completion (week 6),
that is, a single intravenous NSAID injection, was necessary
for two animals (4%) in the IVP group and for nine animals
(36%) in the CP group, which was statistically significant
(P< 0.001), yet did not substantially influence the later
scorings of these animals at week 12 and 18.
In total, three AEs were observed in 3 animals out of 75
allocated to treatment, all diagnosed as mild infections of
the upper respiratory tract showing nasal discharge. Two of
the AEs were observed in the IVP group and one in the CP
group (4.0% in both groups) with no statistically significant
difference between groups (P = 1.000). Neither of the AEs
was serious nor regarded as related to the study treatment.
At the reduced lameness assessment on day 2, no statis-
tical significant difference between groups was observed
(P= 1.000).
There was no significant difference between groups in the
frequency of local reactions (joint effusion, heat at palpa-
tion, and pain to pressure) within the first 2 days after
treatment (P > 0.999). In one animal (2%) in the IVP group,
joint swelling and heat at the injection site worsened from
day 1 to 2 by one score point and pain to pressure worsened
in another animal (2%) from day 1 to 2 by one score point.
In the CP group, increased joint swelling was observed in
Table 2. Evaluation of Inclusion Criteria for Both Treatment Groups
Baseline parameters IVP (N = 50) CP (N= 25) Comparison P value
Age in years
Mean (SD) 9.9 (3.42) 10.1 (4.81) 0.702a
Min–max 3–17 5–23
Median 10.0 9.0
Q1–Q3 7.0–12.0 6.0–12.0
Gender, n (%)
Gelding 11 (22) 5 (20) 0.152b
Mare 18 (36) 4 (16)
Stallion 21 (42) 16 (64)
AAEP score, n (%)
2 = lameness difficult to observe 28 (56) 12 (48) 0.516c
3 = lameness consistently observable 22 (44) 13 (52)
Flexion score, n (%)
1 =mild response 24 (48) 13 (52) 0.746c
2 =moderate response 26 (52) 12 (48)
Pain score, n (%)
0 = no pain to pressure 37 (74) 16 (64) 0.373c
1 =mild pain to pressure 13 (26) 9 (36)
Heat score, n (%)
0 = no increased temperature 31 (62) 16 (64) 0.867c
1 =mild increased temperature 19 (38) 9 (36)
Swelling score, n (%)
1 =mild swelling 18 (36) 14 (56) 0.101c
2 =moderate swelling 32 (64) 11 (44)
aP values are based on the Wilcoxon rank-sum statistic.
bP value is based on the Fisher’s exact test.
cP values are based on the Mantel–Haenszel chi-square statistic.
AAEP, American Association of Equine Practitioners; CP, control product; IVP, investigational veterinary product; Q, Quartile; SD,
standard deviation.
Table 3. Distribution of Horse Improvement
Scores as Indicated by the Owners
at Week 6 After Treatment
Score IVP (N = 50)
CP
(N= 25)
Total
(N = 75)
Comparison
P value
Horse improvement
0% 1 (2%) 9 (36%) 10 (13%) <0.001
20% 6 (12%) 10 (40%) 16 (21%)
40% 4 (8%) 0 (0%) 4 (5%)
60% 3 (6%) 6 (24%) 9 (12%)
80% 16 (32%) 0 (0%) 16 (21%)
100% 20 (40%) 0 (0%) 20 (27%)
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one animal (4.0%) from day 1 to 2. From week 3 to 18
onward, animals in the IVP group demonstrated signifi-
cantly (P < 0.001) less joint effusion, of which 68%–78% of
the horses were without joint swelling from week 6 onward
in comparison to 49%–57% in the CP group (Fig. 4).
The presence of pain to pressure at the injection site was
not significantly different at observations at week 3 and 6
(P ‡ 0.071) with the majority of animals in both groups
(ranging from 88.0% to 100%) showing no local pain to
pressure. Although significantly lower scores were observed
in the IVP group than in the CP group at weeks 12 and 18
(P < 0.015), the majority of animals (ranging from 87.5% to
100%) of both groups showed no local pain to pressure at
these observations. Except for week 6 (P< 0.05), the pres-
ence of heat at the injection site was not significantly dif-
ferent between groups on any postbaseline day (P> 0.149).
FIG. 5. The distribution of
the horses (in percentages) over
the clinical improvement cate-
gories indicated by the owners
at week 6 for both treatment
groups. There was a significant
difference (P< 0.001) between
the IVP and placebo control
(CP) group for each score
category.
FIG. 6. The distribution of
the horses (in percentages) over
the working status categories
indicated by the owner per time
point for the IVP-treated group
and placebo control (CP)-
treated group. The asterisk (*)
indicates a significant differ-
ence in frequency of scores
between the two treatments
groups (P< 0.001).
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However, the majority of animals in both groups (ranging
from 95.8% to 100%) showed normal temperature at the
injection site.
Discussion
In this study, 75 horses with naturally occurring fetlock
joint inflammation were enrolled, of which 50 horses were
treated with allogeneic chondrogenic induced MSCs com-
bined with EAP (IVP) and 25 with a placebo, being 0.9%
NaCl (CP). Such negative controlled study tends to be a
challenge, especially to convince owners to participate, but
was necessary due to the lack of a licensed treatment suit-
able for comparison in this study. In this study, exit criteria
had been defined to allow withdrawal of animals from the
study in case of relevant pain, so owners were reassured
their horse would not have to suffer from unnecessary pain
if enrolled in the study. An ethical committee had reviewed
the study protocol before implementation.
Relevant clinical improvement and effusion scores in-
creased or remained stable in the IVP-treated group from
week 3 toward week 18, whereas the opposite trend was
present in the CP-treated horses. Interestingly, 20%–25% of
the saline-treated horses also demonstrated relevant clinical
improvement at a certain time point. This could be due to
the adjusted training program or to the therapeutic effect of
saline as CP, which has been reported previously [31].
Nevertheless, for all observed parameters, clinical im-
provement decreased over time in the CP group. In the IVP
group, the negative joint flexion also decreased from 84% of
the horses at week 6 to 62% of the horses at week 18.
However, at the long-term follow-up of 1 year, 84% of the
horses in the IVP group were working at training level or
their previous level, indicating a long-term sustainability of
the IVP-treated joints.
In this study, EAP from a single donor horse was added to
the ciMSCs, which is meant to improve MSC proliferation
and chondrogenic differentiation [32]. Indeed, when using
EAP, the manufacturing process needs to be well controlled
and standardized to produce a reproducible product and to
reduce white and red blood cells as much as possible to pre-
vent transfusion-related erythrolysis. In this study, a single
injection of allogeneic EAP and MSCs was performed and did
not cause any sign of product-related AEs. Nasal discharge
was observed in some animals of both groups, indicating
typical seasonal disease during the fall and winter months.
They were considered not to be related to the treatment.
In general, allogeneic MSCs are being considered equally
immunomodulating as autologous MSCs in vitro [33,34]
and in vivo [35,36], but it has been reported that repeated
intra-articular administration of allogeneic equine MSCs
may cause a significant increase in total nucleated cell count
[37]. This increase was still within acceptable clinical ran-
ges [38] and another study reported no AEs after repeated
injection of pooled allogeneic MSCs [39]. However, it
should be considered that MSCs are heterogeneous in MHC
II expression [40], and should therefore be tested in vitro
before clinical application, as reported in this study. More-
over, certain inflammatory parameters can upregulate MHC
molecules, which increases the chances for graft rejection
[40,41]. This could also explain the increase in total nu-
cleated cell count as mentioned above [37].
In this regard, a recent study reported a reduced MHC
expression after pretreating MSCs with transforming growth
factor-b (TGF-b) [42]. Since this happens to be one of the
cartilage stimulating growth factors used in this study to
chondrogenically predifferentiate the MSCs, it might ex-
plain why a very low number of horses presented with
clinical signs of inflammation after the injection. Moreover,
the MHC I level on peripheral blood-derived MSCs is below
10% [17], offering another explanation for the low number
of horses with clinical signs of inflammation in this study.
The patients in this study were also not matched with the
donor MSCs and since no clinical problems were detected,
this further confirms the low immunogenicity of the donor
cells. Nevertheless, it should be mentioned that all horses in
this study received a single injection of ketoprofen (NSAID)
on the day of intra-articular injection, which may have
masked a potential increase of nucleated cells; horses were
injected only once with the IVP. Further research with re-
peated injections using the IVP without NSAID adminis-
tration should provide more insights in this matter and
determine whether the same safety and efficacy can be ob-
served after repeated injections. It would also be interesting
to evaluate antibody response in future studies and deter-
mine whether the same clinical results would be achieved
with another donor horse (with planned donor/acceptor
mismatch) or another dose.
Another important and underestimated aspect of the use
of regenerative medicinal products is the use of an optimal
dose. Consideration of the lowest effective dose for allo-
geneic MSC therapy is of highest importance, because high
doses (30–50 million) of allogeneic equine MSCs could
induce antibody responses in vivo [43]. Based on previous
clinical studies to evaluate the effect of allogeneic ciMSCs
[17,23], the dose of ciMSCs used in the IVP in this study
was set at 2 million cells, which is 5–25-fold lower than the
reported 10–50 million MSCs used in other equine studies
[15,24,37,43,44]. Similarly, it has been described in dogs
that higher treatment doses (66 million) of allogeneic MSCs
result in lameness and pain, whereas this was not the case
with lower doses (5 million) [45].
Even though dose-dependent effects have been reported
for allogeneic MSCs for the treatment of myocardial in-
farction in rats [46] and graft versus host disease in mice
[47], others have also demonstrated a superior outcome
using a lower dose of allogeneic MSCs for treatment of
injured medial collateral ligaments of rat knees [48] or for
the treatment of human knee osteoarthritis [49]. In addition,
after an intravenous injection of allogeneic adipose-derived
MSCs in cats with chronic kidney disease, dose-related
adverse effects were observed [50]. After reducing the dose
from 4 to 2 million MSCs per mL, limited adverse effects
and clinically interesting results [51] were noticed by the
authors. All these findings confirm that the selection of the
dose of allogeneic MSCs needs careful consideration.
In this study, no treatment group was included that only
received the excipient EAP. However, no animals were
treated with EAP alone to reduce the number and use of
animals. Moreover, The IVP consists of a proprietary
combination of allogeneic ciMSCs and EAP. Thus, horses
would never be treated with EAP alone. In addition, the
main contribution of EAP to the ciMSCs is a significant
increase in cell viability after thawing of frozen ciMSCs
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(3%–8% increase in viability depending on storage duration
of the ciMSCs P< 0.05: Data not shown). Because the
thrombocyte specifications of EAP are within physiological
range (75,000–300,000/mL) [52], no influence of the EAP on
the healing process is expected.
On the other hand, when producing actual platelet-rich-
plasma (PRP) with platelet levels more than double of the
physiological platelet levels, a short-term significant in-
crease in white blood cell counts, prostaglandin E2, and total
protein concentrations was detectable in synovial fluid anal-
ysiswithin 6–48h after injection into equine fetlock joints [53].
In the proof-of-concept study performed with the IVP (in-
cluding EAP), no such findings were visible at any of the re-
ported time points (unpub. obsvns.). Moreover, in a previous
study, we demonstrated that ciMSCs in combination with al-
logeneic plasma result in significant increased clinical out-
comes in comparison to allogeneic plasma treatment alone in
fetlock joints [17].
Lameness was evaluated using visual assessment and the
AAEP scoring system and not by an objective measuring
tool such as a lameness locator. However, the use of this
AAEP score system was just, since Keegan et al. [54] stated,
‘‘Such objective measures may augment, but not replace
results obtained by subjective evaluation of lameness in
horses.’’ Although the lameness locator system demon-
strated to have a better interobserver repeatability than a
subjective lameness examination [55,56], the system is still
flawed and not accepted as the gold standard for lameness
evaluation in the literature [54,55]. In addition, the lameness
locator system only takes into account vertical head and
pelvis movement and leaves out several different other ki-
nematic parameters, which can indicate lameness (eg, de-
creased maximum fetlock extension and decreased limb
retraction or protraction).
In the subjective lameness examination, however, the
examining veterinarian can take all these parameters into
account. Moreover, studies on the repeatability of subjective
lameness examination are often based on assessment of vi-
deo tapes without sound and a shot from only one angle and
assessing only one circumstance, while it has been demon-
strated that a full live lameness examination improves in-
terobserver agreement of a subjective lameness examination
[55,57–59].
However, recognizing the limitations of a subjective
lameness examination, some preventive measures were ta-
ken to increase objectivity: (1) horses were only included if
they presented with an initial lameness score of 2 or 3 on the
AAEP scale (consistent lameness), (2) lameness was con-
firmed for that limb by intra-articular anesthesia and a
positive flexion test, (3) the examiner was blinded for
treatment, but not for the initial side of lameness, facilitating
lameness detection for that particular limb, (4) subjective
examination was performed in exactly the same way for
placebo-treated and IVP-treated horses, so any bias gener-
ated during the subjective lameness examination would have
been the same for the two treatment groups, and (5) all
lameness examination was performed by experienced vet-
erinarians.
In conclusion, our results indicate that 2 million alloge-
neic chondrogenic induced MSCs with EAP administered
once in the joint has a similar safety profile and superior
efficacy compared to a placebo in the treatment of inflam-
matory fetlock joint disease in horses. Indeed, besides nasal
discharge in both treatment groups, no AEs were observed
during the entire study period. Moreover, the effect of the
IVP was proven for the duration of 18 weeks based on
relevant clinical improvement, namely a decrease in lame-
ness scores, a decrease in response to flexion, and a decrease
in joint effusion. Furthermore, the effect of the treatment
was confirmed to sustain 1 year after administration, with
significantly more horses working at their previous level or
at training level at this point compared to the placebo con-
trol group.
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